Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects With Depressive Episodes Associated With Bipolar I or II Disorder
Latest Information Update: 22 Feb 2025
At a glance
- Drugs Desmethyl cariprazine prodrug (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Acronyms CANTO; CANTO - (BP-D)
- Sponsors AbbVie
Most Recent Events
- 16 Dec 2024 Planned End Date changed from 10 May 2026 to 1 Apr 2026.
- 16 Dec 2024 Planned primary completion date changed from 10 Apr 2026 to 1 Mar 2026.
- 17 Oct 2024 Status changed from not yet recruiting to recruiting.